Shopping Cart

Your shopping cart is currently empty

HP-β-CD

Name: HP-β-CD
Brand: TargetMol
SKU: T19609
Price: 33 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex) Copy Product Info

🥰Excellent

Synonyms: Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex

Catalog No. T19609 Copy Product Info

Purity: 98%

🥰Excellent

HP-β-CD (Hydroxypropyl betadex) is a water-soluble cyclodextrin derivative obtained by hydroxypropylation of β-cyclodextrin. HP-β-CD serves as a drug delivery carrier that enhances stability and bioavailability.

Cas No. 128446-35-5

Pack Size	Price	USA Stock	Global Stock
500 mg	$33	In Stock	In Stock
1 g	$48	In Stock	In Stock
5 g	$68	-	In Stock
10 g	$89	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98%

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	HP-β-CD (Hydroxypropyl betadex) is a water-soluble cyclodextrin derivative obtained by hydroxypropylation of β-cyclodextrin. HP-β-CD serves as a drug delivery carrier that enhances stability and bioavailability.
Targets & IC50	leukemia cell:3.86–10.09 mM, SKOV3 cells:1.94 μM
In vitro	Methods: Cheliensisin A native compound and its HP-β-CD inclusion complex (compound:HP-β-CD molar ratio 1:2) were added to SW1116, SMMC-7721, and HEK293T cells. Drug concentration gradient: 0–100 μM. Treatment duration: 24 hours. Cell viability was assessed using the MTT assay. Results: The inclusion complex significantly enhanced cytotoxicity against tumor cells. For SW1116 cells, the IC₅₀ of the cheliensisin A inclusion complex decreased from 93.2 to 51.4 μM. The inclusion complex also exhibited increased toxicity toward HEK293T cells. [1] Methods: Human aortic smooth muscle cells (HASMCs) were treated with HP-β-CD (6, 8, 10 mg/mL) for 24 h, followed by Western blot analysis of apoptosis markers. Results: HP-β-CD dose-dependently inhibited VSMC apoptosis. [2]
In vivo	Methods: Male C57BL/6J mice were used in a PCSK9/angiotensin II (AngII)-induced AAA model. HP-β-CD (200 µl/mouse) was administered intraperitoneally twice weekly starting at the initiation of AngII infusion, continuing for 4 weeks. Results: HP-β-CD significantly reduced the maximum diameter of the abdominal aorta and the incidence of AAA, while also mitigating elastin degradation and VSMC apoptosis. [2]
Synonyms	Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex

Chemical Properties

Molecular Weight	1541.547
Formula	C₆₃H₁₁₂O₄₂
Cas No.	128446-35-5
Smiles	CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)O[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O
Relative Density.	1.05 g/cm3 at 20.3℃

Storage & Solubility Information

Storage

Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 45.00 mg/mL (29.19 mM), Sonication is recommended.

H2O: 50.00 mg/mL (32.43 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (1.3 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	0.6487 mL	3.2435 mL	6.4870 mL	32.4350 mL
5 mM	0.1297 mL	0.6487 mL	1.2974 mL	6.4870 mL
10 mM	0.0649 mL	0.3243 mL	0.6487 mL	3.2435 mL
20 mM	0.0324 mL	0.1622 mL	0.3243 mL	1.6217 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.